💊 Biocon Limited Infuses ₹315 Crore Into Subsidiaries to Strengthen Pharma Expansion

Biocon Limited has announced a fresh capital infusion of over ₹315 crore into its wholly owned subsidiaries, reinforcing its long-term pharmaceutical growth strategy. The investment, disclosed on March 3, 2026, involves the subscription of Optionally Convertible Redeemable Preference Shares (OCRPS) in Biocon Biosphere Limited (BBSL) and Biocon Pharma Limited (BPL). Biocon invested ₹115.34 crore in BBSL, primarily aimed at supporting working capital and capital expenditure requirements for its API fermentation and injectable facilities. Notably, a significant portion of this investment involved conversion of earlier loans into preference shares, reflecting internal balance sheet restructuring. Additionally, ₹200 crore was infused into BPL to support working capital and general corporate needs. BPL has demonstrated steady revenue growth over the past three years, reaching ₹9,825 million in FY25, signaling strengthening traction in global generics markets. The transaction does not alter ownership structure, as both entities remain wholly owned subsidiaries. While the move may not immediately impact earnings per share, it strengthens operational capacity and financial stability at the subsidiary level. Strategically, the capital infusion underscores Biocon’s commitment to scaling manufacturing capabilities and enhancing global competitiveness. Investors may view this as a long-term positive, particularly if expansion efforts translate into improved margins and revenue growth in the coming quarters.